Dr. Andreas Muench, M.D.
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical School at Houston (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,696
Licensed in Alabama since 2005, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Texas Medical School at Houston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
AL license 26584 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Southeast Health Medical Center Dothan, AL
- Jackson Hospital Marianna, FL
- Medical Center Enterprise Enterprise, AL
- Medical Center Barbour Eufaula, AL
- Donalsonville Hospital Inc Donalsonville, GA
Medical groups
- Houston County Healthcare Authority (253 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,696
- Services billed
- 8,136
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 2,339 | 303 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 1,461 | 862 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,379 | 726 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 877 | 830 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 654 | 244 |
| Injection, regadenoson, 0.1 mg | 633 | 153 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 443 | 205 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 408 | 208 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 254 | 138 |
| Ultrasound of both sides of head and neck blood flow | 240 | 233 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Dothan, AL | 680 |
| Eliquis (apixaban) Other prescribers in Dothan, AL | 649 |
| Atorvastatin Calcium Other prescribers in Dothan, AL | 647 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Dothan, AL | 526 |
| Metoprolol Tartrate Other prescribers in Dothan, AL | 500 |
| Carvedilol Other prescribers in Dothan, AL | 499 |
| Metoprolol Succinate Other prescribers in Dothan, AL | 427 |
| Entresto (sacubitril/valsartan) Other prescribers in Dothan, AL | 416 |
| Furosemide Other prescribers in Dothan, AL | 408 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Dothan, AL | 319 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 68 payments worth $2,153 in total to this clinician.
| Medtronic, Inc. | $902 |
|---|---|
| Zoll Services LLC (a/k/a Zoll Lifecor Corp) | $227 |
| Abiomed | $206 |
| Shockwave Medical, Inc | $153 |
| Pfizer Inc. | $92.46 |
| E.r. Squibb & Sons, L.l.c. | $77.55 |
| Novartis Pharmaceuticals Corporation | $71.97 |
| Merck Sharp & Dohme LLC | $60.74 |
| Food and Beverage | $1,539 |
|---|---|
| Travel and Lodging | $613 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medtronic, Inc. Nov 11, 2025 | Travel and Lodging COREVALVE EVOLUT R · Transcatheter Valve Systems · travel to Orlando, FL · in-kind | $578 |
| Medtronic, Inc. Nov 11, 2025 | Travel and Lodging COREVALVE EVOLUT R · Transcatheter Valve Systems · travel to Orlando, FL · in-kind | $35.07 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $890,147 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
Eli Lilly and Company · Active, not recruiting · NCT06292013 - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly…
Amgen Inc. - A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease
Novartis Pharmaceuticals Corporation - A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.